Learn Mode

NVO - Novo Nordisk A/S

462

$40.52

-$0.41 (-1.002%)

At market close

$40.65

$0.13 (0.321%)

After Hours 4/17/26, 11:58 PM

Score

4.11/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

NVO

Valuation Score

View as %

Stock Unlock

YTD

Max

Stock Profile

Showing data forNOVO B.CO

Market Cap

DKK 1.14T

Industry

Pharmaceuticals

EPS (TTM)

DKK 23.00

P/E (TTM)

11.16

Div & Yield

DKK 11.70 (4.49%)

FCF Payout Ratio

177.16%

P/S (TTM)

3.70

P/B

5.89

Diluted Shares

4.44B

Ex-Dividend

2026-03-27

Next Earnings

05-06

Forward P/E

12.15

Payout Ratio

50.14%

P/FCF (TTM)

39.43

FCF Yield

2.54%

Earnings Yield

8.96%

52 Week Range

Score Card

Showing data forNOVO B.CO

Explore Scores Tab

4.11

Good

Novo Nordisk A/S has grown revenue at 6.43% over the past year, which suggests sales are increasing. Also, it has seen its net income increase by 1.43% over the past year, which suggests its profits are growing modestly.

Valuation Model

Key Score

2.00

Bad

Management

3.00

Average

Growth

4.00

Good

Profitability

3.00

Average

Fin. Health

1.00

Very Bad

Dividends

5.00

Very Good

Analyst

5.00

Very Good

Insider Transactions

Explore Insider Tab

Insufficient Insider data to display this section

Market News

Page 1 of 5

Novo Nordisk (NVO) Stock Slides as Market Rises: Facts to Know Before You Trade news thumbnail

Novo Nordisk (NVO) Stock Slides as Market Rises: Facts to Know Before You TradeThe latest trading day saw Novo Nordisk (NVO) settling at $40.52, representing a -1% change from its previous close....

Yahoo - 4/17/2026, 9:45:02 PM

Novo Nordisk’s Wegovy Wins EMA Flexibility In GLP-1 Access Push news thumbnail

Novo Nordisk’s Wegovy Wins EMA Flexibility In GLP-1 Access PushNovo Nordisk has received EMA approval to allow Wegovy injections to be stored at up to 30°C for up to 48 hours. The change reduces strict cold chain requirements for ph...

Yahoo - 4/17/2026, 6:04:26 PM

Health Care Up Ahead of Earnings - Health Care RoundupHealth-care companies rose ahead of earnings in the sector. UnitedHealth Group rose ahead of the health-insurance giant's earnings report Tuesday. Eli Lilly shares ralli...

Finnhub - 4/17/2026, 5:05:47 PM

LLY's Oral GLP-1 Pill Foundayo Shows Heart Benefits in Diabetes Study news thumbnail

LLY's Oral GLP-1 Pill Foundayo Shows Heart Benefits in Diabetes StudyLLY's oral GLP-1 pill Foundayo shows cardiovascular benefits, weight loss, and strong glucose lowering in a phase III study as the FDA seeks more safety data....

Yahoo - 4/17/2026, 4:53:00 PM

China Diabetes Devices Market Forecast and Company Analysis Report 2026-2034 Featuring Roche, Abbott Laboratories, Novo Nordisk, BD, Medtronic, Eli Lilly, and SanofiThe China Diabetes Devices Market is projected to grow from USD 7.19 billion in 2025 to USD 14.51 billion by 2034, marking a CAGR of 8.11% from 2026 to 2034. This growth...

Yahoo - 4/17/2026, 4:00:00 PM

Eli Lilly's Pill Lags Novo Nordisk's In First Week. Why Stock Rallied. news thumbnail

Eli Lilly's Pill Lags Novo Nordisk's In First Week. Why Stock Rallied.Eli Lilly's oral weight-loss drug, Foundayo, nabbed 1,390 prescriptions in its first week on the market, analysts said Friday....

Yahoo - 4/17/2026, 2:04:16 PM

Eli Lilly Weight-Loss Pill Prescriptions Near 1,400 in First Week news thumbnail

Eli Lilly Weight-Loss Pill Prescriptions Near 1,400 in First WeekEarly uptake starts modestly as competition with Novo Nordisk remains intense...

Yahoo - 4/17/2026, 2:02:06 PM

7 Health Care Stocks Whale Activity In Today's Session ...

Benzinga - 4/17/2026, 1:35:23 PM

Kailera Therapeutics Debut Marks Largest Biotech IPO Since 2021 Amid Weight Loss Race news thumbnail

Kailera Therapeutics Debut Marks Largest Biotech IPO Since 2021 Amid Weight Loss RaceKailera Therapeutics prices $625 million IPO, advances GLP-1 obesity pipeline as trial data highlights oral ribupatide weight loss results....

Benzinga - 4/17/2026, 1:23:00 PM

Novo Nordisk Extends Lead As Eli Lilly New Obesity Pill Sees Modest Launch Uptake news thumbnail

Novo Nordisk Extends Lead As Eli Lilly New Obesity Pill Sees Modest Launch UptakeEli Lilly obesity pill logs 1,390 U.S. scripts in first week, trailing Novo's oral Wegovy as competition in weight-loss drugs intensifies....

Benzinga - 4/17/2026, 12:04:21 PM

Lilly's Foundayo hits 1,390 prescriptions in debut week news thumbnail

Lilly's Foundayo hits 1,390 prescriptions in debut weekApril 17 (Reuters) - Eli Lilly's newly launched obesity pill was prescribed 1,390 times in the U.S. as of the week ended April 10, according to an analyst who cited IQVI...

Yahoo - 4/17/2026, 10:55:09 AM

Multinational giants step up presence in north China's tech zone TEDA news thumbnail

Multinational giants step up presence in north China's tech zone TEDATIANJIN, China, April 17, 2026 (GLOBE NEWSWIRE) -- The China Development Forum 2026 was recently held in Beijing, drawing nearly 100 global business leaders. Meanwhile, ...

Yahoo - 4/17/2026, 10:13:00 AM

Page 1 of 5

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-04-14

High:

$71.53

76.5%

Avg:

$49.16

21.3%

Low:

$27.12

-33.1%

(% change is relative to the current stock price: $40.52)

Analyst Recommendations

Go to Analyst Tab

3.38

Average

14%

Strong Buy (5)

19%

Buy (7)

62%

Hold (23)

Sell (1)

Strong Sell (1)

About

Website
https://www.novonordisk.com/
Address
Novo Alle 1, Bagsvaerd , DK

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

IPO Date

1974-05-17

Industry

Pharmaceuticals

Total Employees

68,794

Exchange

Omx Nordic Exchange Copenhagen A/S

Reporting Currency

DKK

GICS

Pharmaceuticals

GICS Sub

Pharmaceuticals

GICS Sector

Health Care

GICS Group

Pharmaceuticals, Biotechnology & Life Sciences

Similar Stocks

Compare In Free Form

ALK B.CO

0.67%

ALK-Abello A/S

DKK 211.00DKK 46.7B

HLUN A.CO

1.45%

H Lundbeck A/S

DKK 35.10DKK 33.2B

PEG.CO

6.28%

Pharma Equity Group A/S

DKK 0.09DKK 101.6M

STENO.CO

-3.11%

Stenocare A/S

DKK 1.00DKK 44.5M

NOVO B.CO

1.24%

Novo Nordisk A/S

DKK 260.40DKK 1.1T